Croatian Experience with Sibutramine in the Treatment of Obesity – Multicenter Prospective Study by Davor Štimac et al.
Coll. Antropol. 28 (2004) 1: 215–221
UCD 616-056.52:616-085(497.5)
Original scientific paper
Croatian Experience with Sibutramine
in the Treatment of Obesity –
Multicenter Prospective Study
Davor [timac1, Alen Ru`i}2 and Sanja Klobu~ar Majanovi}3
1 Department of Internal Medicine, University Hospital Center »Rijeka«, Rijeka, Croatia
2 Department of Cardiology, Thalassotherapia, Opatija, Croatia
3 Department of Physiology and Immunology, School of Medicine, University of Rijeka, Rijeka,
Croatia
A B S T R A C T
Obesity is a chronic disease with a marked impact on health and the prevalence of
obesity in Croatia is rapidly rising. Since obesity plays a significant role in the etiology
of cardiovascular diseases, diabetes mellitus type 2 and of some cancers, it is an obvious
target of public health activities. Weight-reducing drugs, like sibutramine, in combina-
tion with diet, exercise and behavioral changes have a role in the management of obe-
sity. Sibutramine acts centrally as a serotonergic and noradrenergic reuptake inhibitor.
It reduces body weight by enhancing satiety and stimulating thermogenesis. The aim of
this multicenter prospective study was to evaluate the efficacy, tolerability and safety
profile of sibutramine in the treatment of overweight patients in Croatia. Patients re-
ceived 10 mg of sibutramine daily for 12 weeks. The main outcome measures were chan-
ges in body weight, BMI, waist and hip circumferences, laboratory assessments (serum
triglicerida, cholesterol, glucose, HbA1c), blood pressure and heart rate profile. Of 461
patients included (mean BMI = 35.816.48 kg/m2, mean age = 43.6510.90 years), 392
completed the study. Three months of sibutramine treatment lead to a significant reduc-
tion in body weight, BMI, waist and hip circumferences and improvement in metabolic
parameters. Loss of over 5% of their initial body weight was found in 359 patients
(91.58%), while 179 patients (45.66%) achieved weight loss over 10%. A decrease of both
systolic (–3.39%) and diastolic (–3.75%) blood pressure was noted, while the pulse rate
rose slightly (0.13%). Adverse events were reported by 124 (26.90%) patients, but they
precipitated only 17 (3.69%) withdrawals. Results of our study confirmed that sibu-
tramine is an effective and safe weight-reducing drug.
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Introduction
The World Health Organization has
described obesity as a global epidemic
that increases the risk of morbidity and
mortality in a number of diseases, nota-
bly type 2 diabetes, dyslipidemia, hyper-
tension and cardiovascular diseases. It
also plays a role in the etiology of cancer,
musculoskeletal disorders and mental
health problems1.
According to the epidemiological study
called »The First Croatian Health Pro-
ject« 79.2% of men and 49.9% of women in
Croatia are overweight (BMI > 25 kg/ m2)
and 31.1% men and 15.2% women are
obese (BMI > 30 kg/m2)2. Despite the dev-
astating health consequences of obesity,
the effects of the preventive measures are
still poor; moreover, doctors most often
treat the complications rather than the
underlying condition obesity itself.
Pharmacological therapy has been
proposed as an adjunct to lifestyle modifi-
cations, reduced caloric intake and exer-
cise in struggling with excessive body
weight3–5. Sibutramine is an antiobesity
drug that acts centrally as a serotonergic
(5-HT) and noradrenergic (NA) reuptake
inhibitor6–8. It reduces body weight by en-
hancing satiety and stimulating thermo-
genesis.
The aim of the present multicenter
prospective study was to evaluate the ef-
ficacy, tolerability and safety profile of
sibutramine in the treatment of over-
weight patients in Croatia.
Patients and Methods
A total of 461 obese adults (mean BMI
= 35.81  6.48 kg/m2, mean age = 43.65 
10.90 years) were enrolled in the study.
Patients were recruited from 47 different
hospital and primary care sites in Croa-
tia. Inclusion criteria were BMI = 30 kg/
m2 or BMI = 27 kg/m2 in patients with
co-morbidities (diabetes mellitus type 2,
dyslipidemia, hypertension). We enrolled
45 patients (11.48%) with diabetes mel-
litus: 12 patients (3.06%) were on met-
formin therapy and 2 patients (0.51%) on
insulin.
Those with hepatic or renal dysfunc-
tion, a history of heart failure, ischaemic
heart disease, stroke, transient ischaemic
attacks, unstable hypertension and sig-
nificant neurological or psychological ill-
ness were excluded.
Participants received 10 mg of sibu-
tramine daily for 12 weeks. The dosage of
sibutramine was increased to 15 mg after
4 weeks if weight loss during that period
was less than 2 kg. Suggestions on diet
and behavioral modifications were pro-
vided: the patients were suggested to make
lifestyle interventions, to increase physi-
cal activity and to reduce the food intake
(mildly reduced calorie diet). This behav-
ior changes were not obligatory.
Efficacy assessments were changes in
body weight, BMI, waist and hip circum-
ferences, laboratory parameters (serum
triglycerides, cholesterol, glucose, HbA1c),
blood pressure and heart rate profile. The
statistical analysis was performed using
the SPSS version 11 software package.
Data were analyzed by paired Student’s t
test. p value < 0.05 was considered signif-
icant.
Results
Of the initial 461 patients, 392 com-
pleted the study (109 men, 283 women)
and 69 withdrew (Figure 1). Adverse
events precipitated 17 (3.69%) withdraw-
als. Only 4 (0.87%) patients specified a
lack of efficacy as a cause of their with-
drawal. Among those completing the stu-
dy, there were 131 (33.42%) patients with
hyper lipidemia, 122 (31.12%) patients
with the history of hypertension and 45
(11.48%) patients with type 2 diabetes.
Concomitant therapy was allowed (Fig-
ure 2).
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After 12 weeks of treatment with si-
butramine, 359 (91.58%) patients lost >
5% of their initial body weight and 179
(45.66%) achieved a weight loss of > 10%.
It was an evident and almost linear pro-
gressive weight loss throughout the study
(Figure 3). Significant reduction in an-
thropometric parameters was observed;
body weight was reduced for 10.00% (p<
0.001), BMI by 9.89% (p<0.001), waist
circumference for 7.06% (p<0.001), and
hip circumference by 6.37% (p<0.001)
(Table 1).
All metabolic parameters represent-
ing cardiovascular risk factors submitted
positive changes (Table 2). There were
substantial decreases in concentrations
of serum triglycerides (–19.49%, p<0.001),
cholesterol (–9.46%, p<0.001), glucose
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lack of efficacy 4 ( 0.87% )
adverse events 17 ( 3.69% )
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Fig. 2. Concomitant therapy for patients inclu-
ded in the study (N=392).
TABLE 1
CHANGES IN ANTHROPOMETRIC PARAMETERS FROM BASELINE TO THE END OF THE STUDY
(N=392)
Baseline Week 12 Change (%) p
Body weight (kg)
Men 117.97  20.64 106.79  19.59
Women 95.79  16.84 85.97  15.54
Overall 101.96  20.52 91.76  19.17 –10.00 <0.001
BMI (kg/m2)
Men 36.99  6.28 33.48  6.04
Women 35.27  6.50 31.65  5.97
Overall 35.81  6.48 32.27  6.04 –9.89 <0.001
Waist circumfe-
rence (cm)
Men 122.62  16.21 113.73  15.19
Women 104.58  15.33 97.31  14.69
Overall 109.55  17.52 101.82  16.59 –7.06 <0.001
Hip circumfe-
rence (cm)
Men 121.49  14.35 113.58  12.83
Women 121.53  13.96 113.85  13.41
Overall 121.52  14.05 114.78  13.24 –6.37 <0.001
(–5.97%, p<0.001) and HbA1c (–5.11%, p=
0.002).
On average, from baseline to week 12,
there was a significant decrease of sys-
tolic (–3.39%, p<0.001) and diastolic
(–3.75%, p<0.001) blood pressure, while
the pulse rate showed a slight but statis-
tically insignificant increase (+0.13%, p=
0.08) (Table 2).
Adverse events were reported by 124
(26.90%) of patients. The most frequent
were dry mouth, constipation and head-
ache (Figure 4).
Discussion
Obesity is a chronic disease with a
marked impact on health9. Metabolic and
genetic studies proved that obesity arises
from an excess of energy intake compared
to expenditure. Individuals inherit a set
of genes controlling appetite and metabo-
lism that are then acted upon by a wide
variety of environmental factors such as
food availability, level of physical activity,
psychological and cultural factors10,11.
A previous study on obesity carried
out in Croatia provided information on
national and regional patterns of body
weight, nutritional status assessments
and health risk factor correlates of obe-
sity2,12–15.
The prevalence of obesity in Croatia is
rapidly rising. Half of all Croats presently
die of cardiovascular diseases (50.3%), and
additional 20% of neoplasm2. Having in
mind that obesity plays a significant role
in the etiology of cardiovascular diseases,
diabetes mellitus type 2 and of some ty-
pes of cancer; it is obvious that obesity
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Fig. 4. Adverse events registered during the
study (N=392).
TABLE 2
CHANGES IN CARDIOVASCULAR INDICES FROM BASELINE TO THE END OF THE STUDY (N=392)
Baseline Week 12 Change p
Triglicerida (mmol/L) 2.36  1.97 1.90  1.18 –19.49% < 0.001
Cholesterol (mmol/L) 6.13  1.36 5.55  1.03 –9.46% < 0.001
Glucose (mmol/L) 5.86  1.78 5.51  1.41 –5.97% < 0.001
HbA1C (%) 5.87  1.38 5.57  1.51 –5.11% < 0.001
Systolic BP (mmHg) 135.50  18.3 130.90  13.1 –3.39% < 0.001
Diastolic BP (mmHg) 85.38  10.3 82.19  8.0 –3.75% < 0.001
Heart rate (beats/min) 76.82  9.0 76.91  8.4 +0.13% 0.08
should be a target of public health activi-
ties in reducing morbidity and mortality.
Primary preventive strategies should be
focused on younger individuals because,
as our data indicate, two thirds of pa-
tients become overweight before the age
of 30. Another important point of weight
management is the fact that non-phar-
macological therapies fail on a larger sca-
le. Consequently, weight-reducing drugs,
like sibutramine, in combination with diet,
exercise and behavioral changes have an
important role in the management of obe-
sity16,17.
Results of our study confirmed that
sibutramine is effective, safe, and that it
reduces cardiovascular risk factors in
obese patients. Three months treatment
with sibutramine leads to significant re-
duction in body weight, BMI, waist and
hip circumferences and an improvement
of metabolic parameters.
Decrease in waist circumference is par-
ticularly important because it is well known
that intra-abdominal fat accumulation is
associated with a greater risk of cardio-
vascular diseases. Cutoffs indicating a
significantly increased risk are waist cir-
cumference over 80 cm in women and
over 94 cm in men18.
A number of short-term trials have
also demonstrated that sibutramine is able
to promote significant weight loss6,19–23.
Our study was designed very similarly to
the German post marketing surveillance
study on sibutramine in clinical practice.
Within 12 weeks of treatment, 6,360 en-
rolled patients showed a mean body weight
loss of 10.2%, BMI reduction of 10.7%, tri-
glycerides decrease of 13.2%, cholesterol
of 8.7%, glucose of 5.0% and HbA1C of
4.9%, all corresponding to our results24.
The STORM study (Sibutramine Trial
of Obesity Reduction and Maintenance) is
different from other weight loss trials be-
cause it showed not only the efficacy of
sibutramine weight loss, but also indi-
cated that sibutramine therapy could
prevent weight regain for an additional
period of 18 months among patients who
lost over 5% of body weight in the first 6
months phase of the study. In the second
phase, the patients were randomized to
sibutramine or placebo; 43% of sibutra-
mine treated patients maintained at
least 80% of their weight loss in compari-
son to only 16% in the placebo group25.
Reduction in triglyceride levels is also
of great importance. An increase of only 1
mmol/L in triglyceride levels is associated
with an increase of 76% of cardiovascular
disease risk in women and a 31% increase
in men26.
In our study a significant decline in
both, systolic and diastolic blood pressure
was observed. Our results are in accor-
dance with the mentioned German stu-
dy24. However, in most of the other similar
studies, a slight or significant increase in
blood pressure was found6,20,22,25,27–29.
A small increase of the mean pulse
rate observed in our patients is in accor-
dance with other sibutramine stu-
dies6,19–23,25,27,30.
Furthermore, we observed a signifi-
cant, weight-reduction associated impro-
vement in glycemic control that confir-
med the results of previous studies on
sibutramine effectiveness in the treatment
of obese type 2 diabetic patients31–34.
Besides sibutramine, orlistat is an-
other effective anti-obesity drug available
for clinical use35–38. Orlistat acts periph-
erally blocking the dietary fat absorption.
A number of studies have proven the im-
pact of orlistat on weight loss. A recent
study (XENDOS; XENical in the preven-
tion of Diabetes in Obese Subjects) re-
ported results showing that weight loss
achieved with orlistat delays the develop-
ment of diabetes over a 4-year period39. A
comparison study on the efficacy of met-
formin, orlistat and sibutramine in obe-
sity treatment found that sibutramine is
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more effective than orlistat or metformin
in weight reduction. Six months treat-
ment with sibutramine, orlistat and met-
formin showed a significantly reduced
BMI (–13.57%, –9.06% and –9.90% res-
pectively)40.
What can be expected in the future?
Will overweight patients be treated with
a sibutramine-permanant therapy, a si-
butramine/orlistat combination or by us-
ing some new therapeutic strategy, re-
mains to be seen? However, the long-term
benefits of sibutramine therapy require
further evaluation.
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HRVATSKO ISKUSTVO S KORI[TENJEM SIBUTIRAMINA U LIJE^ENJU
PRETILOSTI – MULTICENTRI^NA PROSPEKTIVNA STUDIJA
S A @ E T A K
Pretilost je kroni~na bolest, sa zna~ajnim u~inkom na zdravlje. Prevalencija preti-
losti u Hrvatskoj vrtoglavo raste. Uzimaju}i u obzir da pretilost ima zna~ajnu ulogu u
etiologiji kardio-vaskularnih bolesti, dijabetes mellitusa tip 2 i nekih oblika raka, jasno
je da pretilost treba biti cilj javno-zdravstvenih akcija, s ciljem smanjenja morbiditeta i
mortaliteta u Hrvatskoj. Lijekovi koji sni`avaju te`inu, poput sibutiramina, u kombi-
naciji s dijetom, tjelovje`bom i promjenama pona{anja imaju ulogu u tretmanu preti-
losti. Sibutiramin ima centralno djelovanje kao serotoninergi~ki i noradrenergi~ki in-
hibitor ponovnog unosa. Tjelesnu te`inu smanjuje poticanjem sitosti i poja~anjem ter-
mogeneze. Cilj ove multicentri~ne prospektivne studije bio je evaluacija efikasnosti,
tolerancije i sigurnosti sibutiramina u lije~enju pretilosti u Hrvatskoj. Pacijenti su tre-
tirani s 10 mg sibutiramina dnevno, tijekom 12 tjedana. Glavni promatrani parametri
bili su promjene tjelesne te`ine, BMI, opsega struka i bokova, laboratorijski nalazi (ra-
zina triglicerida u serumu, kolesterol, glukoza, te HbA1c), krvni tlak i sr~ana frekven-
cija. Od 461 pacijenta uklju~enog u studiju (prosje~ni BMI = 35.81  6.48 kg/m2, pro-
sje~na starost = 43.65  10,90 godina), 392 je zavr{ilo studiju. Tri mjeseca tretmana
sibutiraminom rezultiralo je zna~ajnom redukcijom tjelesne te`ine, BMI, opsega stru-
ka i bokova, te pobolj{anje metaboli~kih parametara. Gubitak vi{e od 5% po~etne tje-
lesne te`ine je opserviran u 359 pacijenata (91,58%), dok je 179 pacijenata (45,66%)
postiglo gubitak tjelesne te`ine ve}i od 10%. Uo~eno je sni`enje sistoli~kog (–3,39%) i
dijastoli~kog (–3,75) tlaka, dok je sr~ana frekvencija blago porasla (0,13%). Nuspojave
su prijavila 124 pacijenta (26,90%), ali su uzrokovale samo 17 (3,69%) slu~ajeva ispa-
danja iz studije. Rezultati na{e studije potvr|uju da je sibutiramin efikasan i siguran
lijek za sni`avanje tjelesne te`ine.
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